Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level685 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,087 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07676370 | PROV-MESH: Prophylactic Ovarian Cancer MESH(PROV-MESH) | recruiting | N/A | 152 | Hospital Vall d'HebronOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04387227 | Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 22 | University of WashingtonOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05377996 | A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | recruiting | Phase 1 / Phase 2 | 360 | Day One Biopharmaceuticals, Inc.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05401162 | Chemotherapy Supported by Autologous Hematopoietic Stem Cells | recruiting | N/A | 40 | Chongqing University Cancer HospitalOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05952453 | Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro | recruiting | Phase 2 | 20 | University of Alabama at BirminghamOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07545460 | A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | not yet recruiting | Phase 3 | 404 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673835 | Iparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer（Phase II） | not yet recruiting | Phase 2 | 49 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673861 | Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients(CURTAIN) | recruiting | N/A | 100 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07670962 | Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy | not yet recruiting | — | 300 | Asan Medical CenterOTHER | 0 | Jun 26, 2026 | clinicaltrials |
| NCT03326713 | Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project(GRACE) | completed | N/A | 668 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05185947 | Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04817501 | Phenotypic Spectrum of CTCs in Tumors of the Female Reproductive System(CTCs) | completed | — | 150 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05568680 | SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma | recruiting | Phase 1 | 42 | Verismo TherapeuticsINDUSTRY | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06386653 | Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07387263 | Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing | recruiting | N/A | 180 | Unity Health TorontoOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07664735 | A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. | not yet recruiting | Phase 1 | 30 | Outpace Bio, Inc.INDUSTRY | 0 | Jun 24, 2026 | clinicaltrials |
| NCT07667192 | Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer(Regynera-RT) | recruiting | — | 500 | Affidea Nu-med Center of Oncological DIagnostics and TherapyOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT02489006 | A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer(NEO) | active not recruiting | Phase 2 | 71 | University Health Network, TorontoOTHER | 4 | Jun 23, 2026 | clinicaltrials |
| NCT03393962 | Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors | enrolling by invitation | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03872947 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 138 | Toray Industries, IncINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT05368207 | Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient(Pemb-HT) | completed | N/A | 1 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06660147 | Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer(KELI-PAOLA) | completed | — | 243 | ARCAGY/ GINECO GROUPOTHER | 2 | Jun 23, 2026 | clinicaltrials |
| NCT07432633 | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 1 / Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07663513 | Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer | not yet recruiting | Phase 2 | 36 | Fudan UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05059522 | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | active not recruiting | Phase 3 | 77 | PfizerINDUSTRY | 19 | Jun 22, 2026 | clinicaltrials |
| NCT07660718 | The Use of Artificial Intelligence for Ultrasound Screening of Ovarian Cancer in Postmenopausal Women(ASTOM) | active not recruiting | — | 100 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT02389985 | A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 30 | NewLink Genetics CorporationINDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05071937 | ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer | recruiting | Phase 2 | 33 | Alexander B Olawaiye, MDOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06257264 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | active not recruiting | Phase 1 | 103 | BeiGeneINDUSTRY | 6 | Jun 18, 2026 | clinicaltrials |
| NCT07503808 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | recruiting | Phase 1 | 150 | IDEAYA BiosciencesINDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT04055649 | ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer | recruiting | Phase 2 | 62 | Ira WinerOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05721326 | Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition | completed | N/A | 1,283 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT06543537 | Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer | recruiting | N/A | 112 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07219238 | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | recruiting | Phase 2 / Phase 3 | 175 | GE HealthcareINDUSTRY | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07282158 | Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians | recruiting | N/A | 25 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT06321484 | Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer | recruiting | Phase 1 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06390995 | A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 28 | TakedaINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07651020 | The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors | completed | — | 1 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07651124 | To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer | recruiting | N/A | 6 | Yong Wha MoonOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07647653 | Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian Cancer | not yet recruiting | Phase 2 | 120 | Shandong UniversityOTHER | 0 | Jun 15, 2026 | clinicaltrials |
| NCT07648745 | Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer(CEBOC) | completed | Phase 2 | 30 | Prof Gordon JaysonOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07648940 | Bioequivalence Study of Liposomal Doxorubicin 20 mg/10 mL (Doxopeg® vs Caelyx®) in Advanced Cancer Patients | completed | Phase 1 | 74 | Zodiac Produtos Farmaceuticos S.A.INDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT02759588 | Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer | completed | Phase 1 / Phase 2 | 46 | Genelux CorporationINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04421963 | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib(ROSY-O) | active not recruiting | Phase 3 | 185 | AstraZenecaINDUSTRY | 23 | Jun 12, 2026 | clinicaltrials |
| NCT05075993 | Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | active not recruiting | Phase 1 | 352 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 30, 2026source: clinicaltrials